Press Release Nov 08 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Bisoprolol Fumarate and Hydrochlorothiazide tablets. The tablets are indicated for the treatment of high blood pressure and will be manufactured at the company's facility in Ahmedabad. The press release also notes that the drug had significant annual sales in the United States according to market data.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Press Release Nov 07 2022
- Press Release Nov 03 2022
- Press Release Oct 29 2022
- Press Release Oct 26 2022
- Press Release Oct 22 2022
Later from Zydus Lifesciences
- Press Release Nov 16 2022
- Press Release Nov 23 2022
- Press Release Nov 28 2022
- Press Release Dec 01 2022
- Press Release Dec 02 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences